Constitutively active SPAK causes hyperkalemia by activating NCC and remodeling distal tubules
JournalJournal of the American Society of Nephrology
PublisherAmerican Society of Nephrology
MetadataShow full item record
AbstractAberrant activation of with no lysine (WNK) kinases causes familial hyperkalemic hypertension (FHHt). Thiazide diuretics treat the disease, fostering the view that hyperactivation of the thiazide-sensitive sodium-chloride cotransporter (NCC) in the distal convoluted tubule (DCT) is solely responsible. However, aberrant signaling in the aldosterone-sensitive distal nephron (ASDN) and inhibition of the potassiumexcretory renal outermedullary potassium(ROMK) channel have also been implicated. To test these ideas, we introduced kinase-activating mutations after Lox-P sites in the mouse Stk39 gene, which encodes the terminal kinase in the WNK signaling pathway, Ste20-related proline-alanine-rich kinase (SPAK). Renal expression of the constitutively active (CA)-SPAK mutant was specifically targeted to the earlyDCT using a DCT-driven Cre recombinase. CA-SPAK mice displayed thiazide-treatable hypertension and hyperkalemia, concurrent with NCC hyperphosphorylation. However, thiazide-mediated inhibition of NCC and consequent restoration of sodium excretion did not immediately restore urinary potassium excretion in CA-SPAK mice. Notably, CA-SPAK mice exhibited ASDN remodeling, involving a reduction in connecting tubule mass and attenuation of epithelial sodium channel (ENaC) and ROMK expression and apical localization. Blocking hyperactive NCC in the DCT gradually restored ASDN structure and ENaC and ROMK expression, concurrentwith the restoration of urinary potassiumexcretion. These findings verify that NCC hyperactivity underlies FHHt but also reveal that NCC-dependent changes in the driving force for potassium secretion are not sufficient to explain hyperkalemia. Instead, a DCT-ASDN coupling process controls potassium balance in health and becomes aberrantly activated in FHHt.
SponsorsFunding for this project was provided National Institutes of Health Grants DK63049, DK54231, and DK093501.
Kidney Tubules, Distal--pathology
Sodium Chloride Symporter Inhibitors--pharmacology
Solute Carrier Family 12, Member 3--metabolism
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85025094879&doi=10.1681%2fASN.2016090948&partnerID=40&md5=9ad558349af8804a76d1d302a685ced3; http://hdl.handle.net/10713/11126
- WNK bodies cluster WNK4 and SPAK/OSR1 to promote NCC activation in hypokalemia.
- Authors: Thomson MN, Cuevas CA, Bewarder TM, Dittmayer C, Miller LN, Si J, Cornelius RJ, Su XT, Yang CL, McCormick JA, Hadchouel J, Ellison DH, Bachmann S, Mutig K
- Issue date: 2020 Jan 1
- Disruption of the with no lysine kinase-STE20-proline alanine-rich kinase pathway reduces the hypertension induced by angiotensin II.
- Authors: Cervantes-Perez LG, Castaneda-Bueno M, Jimenez JV, Vazquez N, Rojas-Vega L, Alessi DR, Bobadilla NA, Gamba G
- Issue date: 2018 Feb
- The interplay of renal potassium and sodium handling in blood pressure regulation: critical role of the WNK-SPAK-NCC pathway.
- Authors: Wu A, Wolley M, Stowasser M
- Issue date: 2019 Jul
- Extracellular K<sup>+</sup> rapidly controls NaCl cotransporter phosphorylation in the native distal convoluted tubule by Cl<sup>-</sup> -dependent and independent mechanisms.
- Authors: Penton D, Czogalla J, Wengi A, Himmerkus N, Loffing-Cueni D, Carrel M, Rajaram RD, Staub O, Bleich M, Schweda F, Loffing J
- Issue date: 2016 Nov 1
- A molecular update on pseudohypoaldosteronism type II.
- Authors: Pathare G, Hoenderop JG, Bindels RJ, San-Cristobal P
- Issue date: 2013 Dec 1